Hemogenyx teams up with Johnson & Johnson to develop new lupus treatment

HemoGenyx Pharmaceuticals PLC’s (LON:HEMO) Immugenyx subsidiary is teaming up with US pharma giant Johnson & Johnson to find a new treatment for lupus.

Under the terms of the collaboration agreement with J&J’s Janssen division, Immugenyx will use its advanced hematopoietic chimeras (AHC) to develop a lupus disease model in a humanised mouse with a functional human immune system.

For the full article please click here.